One World One Health: Political and Practical Challenges

9-10 March, 2009, Chatham House, London
A nation's health is no longer its own business. Globalization, increase in population and changes in lifestyle have enabled new infections to emerge and spread rapidly around the world. HIV, SARS and Avian Influenza are but few of the examples - a new disease emerges, on average, every year and at the same time a number of infectious diseases have developed resistance to available treatments. Such problems cannot be managed by nations within their own borders; new directions for global cooperation need to be developed.

This conference will explore global health policy as it intersects with the global political process and propose new ideas for policy and practice in cooperation on global health issues across government departments, between specialist international organisations and between government, the private sector and the NGO community.

Participants from the public and private sectors will bring relevant and current expertise to discuss questions including:

  • How can the divide between donor strategies, national competitiveness and corporate business priorities be bridged?
  • Are there any effective roadmaps for health recovery in post-conflict environments?
  • Are current approaches to domestic security at the border commensurate with the potential health threats?
  • What are the main issues surrounding intellectual property rights and what solutions exist that would support an effective global response to major infectious disease threats such as pandemic influenza?
  • The role and value of innovation: what structures to promote innovation are needed?

For further information and registration, please visit:
http://www.chathamhouse.org.uk/health09

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...